

Anne S Tsao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7422797/publications.pdf>

Version: 2024-02-01

105
papers

9,506
citations

66315

42
h-index

40954

93
g-index

148
all docs

148
docs citations

148
times ranked

10747
citing authors

#	ARTICLE	IF	CITATIONS
1	Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. <i>Annals of Thoracic Surgery</i> , 2022, 113, 200-208.	0.7	16
2	Pozotinib for Patients With <i>HER2</i> Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 702-709.	0.8	53
3	Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1327-1337.	0.4	29
4	Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for <i>KRAS</i> -Mutated Non-Small Cell Lung Cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100514.	0.7	5
5	New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. <i>Journal of Clinical Oncology</i> , 2022, 40, 681-692.	0.8	26
6	Encorafenib plus binimetinib in patients with <i>BRAF</i> ^{V600} -mutant non-small cell lung cancer: phase II PHAROS study design. <i>Future Oncology</i> , 2022, 18, 781-791.	1.1	9
7	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. <i>Lung Cancer</i> , 2022, 167, 8-16.	0.9	9
8	Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline <i>BAP1</i> Mutations. <i>Journal of Thoracic Oncology</i> , 2022, 17, 873-889.	0.5	44
9	Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. <i>Clinical Lung Cancer</i> , 2021, 22, e451-e465.	1.1	26
10	Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 269-277.	0.5	23
11	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2021, 397, 375-386.	6.3	638
12	Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. <i>Scientific Reports</i> , 2021, 11, 4530.	1.6	27
13	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021, 27, 504-514.	15.2	357
14	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial. <i>Cancer Discovery</i> , 2021, 11, 1688-1699.	7.7	154
15	Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With <i>EGFR</i> -Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. <i>JCO Precision Oncology</i> , 2021, 5, 1241-1249.	1.5	11
16	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2021, 9, e002891.		107
17	Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring <i>MET</i> Exon 14 Skipping. <i>JCO Precision Oncology</i> , 2021, 5, 1802-1812.	1.5	9
18	Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 248-257.	0.5	97

#	ARTICLE	IF	CITATIONS
19	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. <i>Clinical Cancer Research</i> , 2020, 26, 5477-5486.	3.2	15
20	A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. <i>Oncologist</i> , 2020, 25, e1457-e1463.	1.9	7
21	A Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and Their Spouses: Results of a Three-Arm Pilot Randomized Controlled Trial. <i>Oncologist</i> , 2020, 25, e1794-e1802.	1.9	35
22	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 176-183.	5.7	201
23	Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. <i>Clinical Lung Cancer</i> , 2020, 21, e294-e301.	1.1	10
24	A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3525-3536.	3.2	22
25	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1449-1459.	0.5	109
26	Reply to Waller et al. Standardizing Surgical Treatment for Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2020, 15, e75-e77.	0.5	1
27	Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). <i>Journal of Clinical Oncology</i> , 2019, 37, 2537-2547.	0.8	36
28	Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1704-1717.	0.5	8
29	Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. <i>Seminars in Oncology</i> , 2019, 46, 145-154.	0.8	14
30	Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 402-429.	157.7	306
31	A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1343-1353.	0.5	41
32	Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naïve patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 569-580.	5.2	117
33	The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1172-1183.	0.5	60
34	Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1718-1731.	0.5	15
35	Return to intended oncologic treatment after surgery for malignant pleural mesothelioma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 924-929.	0.4	7
36	Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database. <i>Journal of Thoracic Disease</i> , 2019, 11, 1269-1278.	0.6	13

#	ARTICLE	IF	CITATIONS
37	Use of Immune Checkpoint Inhibitors in Mesothelioma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 18.	1.3	46
38	Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 960-966.	0.6	19
39	Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. <i>Lung Cancer</i> , 2018, 120, 62-69.	0.9	29
40	The Integrated Genomic Landscape of Thymic Epithelial Tumors. <i>Cancer Cell</i> , 2018, 33, 244-258.e10.	7.7	270
41	Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. <i>International Journal of Radiation Oncology Biology Physics</i> . 2018. 100. 730-737.	0.4	27
42	Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 246-257.	0.5	14
43	Pilot Testing of a Brief Couple-Based Mind-Body Intervention for Patients With Metastatic Non-Small Cell Lung Cancer and Their Partners. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 953-961.	0.6	13
44	American Society of Clinical Oncology Statement: Biosimilars in Oncology. <i>Journal of Clinical Oncology</i> , 2018, 36, 1260-1265.	0.8	88
45	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	0.5	85
46	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , 2018, 8, 1548-1565.	7.7	422
47	Scientific Advances and New Frontiers in Mesothelioma Therapeutics. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1269-1283.	0.5	87
48	Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): A Step Forward in a Long Race. <i>Journal of Thoracic Oncology</i> , 2018, 13, 871-873.	0.5	10
49	A research protocol for a pilot randomized controlled trial designed to examine the feasibility of a couple-based mind-body intervention for patients with metastatic lung cancer and their partners. <i>Pilot and Feasibility Studies</i> , 2018, 4, 37.	0.5	9
50	SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemo-naïve patients with malignant pleural mesothelioma. <i>Journal of Clinical Oncology</i> , 2018, 36, 8514-8514.	0.8	7
51	LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2017, 18, 589-593.	1.1	17
52	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	0.5	40
53	A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017, 23, 7483-7489.	3.2	48
54	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1261-1273.	5.1	356

#	ARTICLE	IF	CITATIONS
55	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. <i>Lung Cancer</i> , 2017, 112, 181-187.	0.9	40
56	Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). <i>Journal of Thoracic Oncology</i> , 2017, 12, 1299-1308.	0.5	24
57	Germline and Somatic Smoothed Mutations in Non-“Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	1.5	3
58	Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO. <i>Journal of Oncology Practice</i> , 2017, 13, e62-e67.	2.5	1
59	Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 8-16.e1.	0.6	53
60	Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2016, 17, e5-e11.	1.1	39
61	Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. <i>Infectious Agents and Cancer</i> , 2016, 11, 21.	1.2	14
62	Consensus Report of the 2015 Weinman International Conference on Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1246-1262.	0.5	122
63	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 1672-1682.	5.1	865
64	Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2761-2768.	0.8	154
65	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016, 11, 613-638.	0.5	231
66	SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM). <i>Journal of Thoracic Oncology</i> , 2015, 10, 387-391.	0.5	67
67	Hemithoracic Intensity Modulated Radiation Therapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Toxicity, Patterns of Failure, and a Matched Survival Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 149-156.	0.4	52
68	Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 998-1007.	0.5	82
69	Current Readings: Window-of-Opportunity Trials for Thoracic Malignancies. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2014, 26, 323-330.	0.4	4
70	Local and Systemic Therapies for Malignant Pleural Mesothelioma. <i>Current Treatment Options in Oncology</i> , 2014, 15, 683-699.	1.3	16
71	Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Chemonaive Patients With Unresectable Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2014, 15, 197-201.	1.1	28
72	Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 140-145.	0.6	9

#	ARTICLE	IF	CITATIONS
73	Immunotherapy in lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 53-63.	1.3	50
74	The Importance of Molecular Profiling in Predicting Response to Epidermal Growth Factor Receptor Family Inhibitors in Non-Small-Cell Lung Cancer: Focus on Clinical Trial Results. <i>Clinical Lung Cancer</i> , 2013, 14, 311-321.	1.1	11
75	Phase II study of TAS-106 in patients with platinum failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. <i>Cancer Medicine</i> , 2013, 2, 351-359.	1.3	10
76	Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial. <i>Journal of Thoracic Oncology</i> , 2013, 8, 658-661.	0.5	19
77	Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2013, 8, 238-245.	0.5	118
78	Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2012, 7, S399-S400.	0.5	1
79	Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1645-1652.	0.5	21
80	The BATTLE Trial: Personalizing Therapy for Lung Cancer. <i>Cancer Discovery</i> , 2011, 1, 44-53.	7.7	778
81	Reply to the Letter to the Editor Entitled A Practical Guide to Measure Malignant Pleural Mesothelioma Tumors by Modified RECIST Criteria?. <i>Journal of Thoracic Oncology</i> , 2011, 6, 2144-2145.	0.5	1
82	Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1938-1945.	0.5	88
83	Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2011, 6, 2104-2111.	0.5	26
84	Mitotic Inhibitors. <i>Journal of Thoracic Oncology</i> , 2011, 6, S1789-S1790.	0.5	1
85	A Practical Guide of the Southwest Oncology Group to Measure Malignant Pleural Mesothelioma Tumors by RECIST and Modified RECIST Criteria. <i>Journal of Thoracic Oncology</i> , 2011, 6, 598-601.	0.5	39
86	Mesothelioma and Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, S1825-S1826.	0.5	1
87	Immunohistochemical Overexpression of Platelet-Derived Growth Factor Receptor- β (PDGFR- β) is Associated With PDGFRB Gene Copy Number Gain in Sarcomatoid Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2011, 12, 369-374.	1.1	34
88	Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III non-small cell lung cancer. <i>Cancer</i> , 2011, 117, 4707-4713.	2.0	157
89	The future of NSCLC: molecular profiles guiding treatment decisions. <i>Oncology</i> , 2011, 25, 607, 614.	0.4	4
90	Future directions in multimodality therapy for NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 10-12.	12.5	4

#	ARTICLE	IF	CITATIONS
91	Individualizing Mesothelioma Treatment: Small Steps Into a Brighter Future. <i>Clinical Lung Cancer</i> , 2010, 11, 371-373.	1.1	4
92	Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions. <i>Cancer Prevention Research</i> , 2009, 2, 931-941.	0.7	210
93	Neoadjuvant and Intrapleural Therapies for Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2009, 10, 36-41.	1.1	21
94	Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2009, 27, 2081-2090.	0.8	323
95	Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib. <i>Journal of Clinical Oncology</i> , 2008, 26, 1472-1478.	0.8	284
96	Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1962-1972.	1.9	118
97	Outcomes After Extrapleural Pneumonectomy and Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>Annals of Thoracic Surgery</i> , 2007, 84, 1685-1693.	0.7	216
98	Clinicopathologic Characteristics of the EGFR Gene Mutation in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 231-239.	0.5	121
99	Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. <i>Cancer</i> , 2006, 106, 2428-2436.	2.0	152
100	Phase I/II Study of Docetaxel, Cisplatin, and Concomitant Boost Radiation for Locally Advanced Squamous Cell Cancer of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2006, 24, 4163-4169.	0.8	59
101	Extended Surgical Staging for Potentially Resectable Malignant Pleural Mesothelioma. <i>Annals of Thoracic Surgery</i> , 2005, 80, 1988-1993.	0.7	80
102	Chemoprevention of Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2004, 54, 150-180.	157.7	275
103	Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. <i>Cancer</i> , 2004, 100, 2240-2245.	2.0	9
104	Imatinib mesylate causes hypopigmentation in the skin. <i>Cancer</i> , 2003, 98, 2483-2487.	2.0	143
105	Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 660-4.	1.1	61